 |
|
Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches
Fatma Majdoub, Hanene Lassoued Ferjani, Dorra Ben Nessib, Dhia Kaffel, Kaouther Maatallah, Wafa Hamdi
Ann Pediatr Endocrinol Metab. 2023;28(2):98-106. Published online 2023 Jun 30 DOI: https://doi.org/10.6065/apem.2346058.029
|
|
Citations to this article as recorded by
 New Perspectives of Therapies in Osteogenesis Imperfecta—A Literature Review
Alexandru Dinulescu, Alexandru-Sorin Păsărică, Mădălina Carp, Andrei Dușcă, Irina Dijmărescu, Mirela Luminița Pavelescu, Daniela Păcurar, Alexandru Ulici
Journal of Clinical Medicine.2024; 13(4): 1065. CrossRef Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model
Mai Morita, Fawaz Arshad, Lewis A. Quayle, Christopher N. George, Diane V. Lefley, Ivo Kalajzic, Meena Balsubramanian, Tugba Cebe, Gwen Reilly, Nicolas J. Bishop, Penelope D. Ottewell
Bone Reports.2024; : 101795. CrossRef Diagnosis and Management of Osteoporosis in Children and Adolescents
Hye Young Jin, Eu Seon Noh, Il Tae Hwang
The Ewha Medical Journal.2023;[Epub] CrossRef Osteogenesis imperfecta: Strengthening knowledge of bones and genes
Shubha R Phadke
Journal of Pediatric Endocrinology and Diabetes.2023; 3: 50. CrossRef
|